Covaxin effective against Brazilian, British and Indian variants of coronavirus, studies show
Bharat Biotech’s Covid-19 vaccine ‘Covaxin’ has demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2, in a new study conducted by the Indian Council of Medical Research (ICMR) in association with the National Institute of Virology.
The Brazilian variant contains the E484K mutation that was found in New York in the United States of America.
A previous study conducted by ICMR had shown that Covaxin is also effective against the UK variant, B.1.1.7, and the Indian double mutant variant, B.1.617.
These studies suggest that Covaxin may be effective against multiple variants of the coronavirus.
“We are pleased to see the results of this study as it demonstrates the potential effectiveness of Covaxin against multiple variants, further strengthening our belief that this vaccine can potentially eliminate the possibility of mutant virus escape,” said Dr. Satish Chandran, chairperson of the vaccine scientific advisory board of Ocugen, on Monday.